Aldebaran Therapeutics

Aldebaran Therapeutics is a private biotechnology company developing precision ocular antisense oligonucleotide medicines for severe blinding diseases. The company focuses on genetically informed eye diseases and applies human genetics, human induced pluripotent stem cell models, and in vivo models to identify and advance candidates. Its technology approach combines Alloy Therapeutics’ genetic medicines capabilities with a proprietary AntiClastic antisense oligonucleotide format intended to improve potency, specificity, and therapeutic index. Aldebaran appears to be an early-stage platform biotech with a diversified preclinical portfolio spanning inherited retinal disease, age-related macular degeneration, and glaucoma.